利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

27 条记录 (耗时 0.037 秒)

    BI-SPECIFIC MONOVALENT DIABODIES THAT ARE CAPABLE OF BINDING TO GPA33 AND CD3, AND USES THEREOF
    12.
    发明公开
    BI-SPECIFIC MONOVALENT DIABODIES THAT ARE CAPABLE OF BINDING TO GPA33 AND CD3, AND USES THEREOF 审中-公开
    双特异性双抗体MONO VALENTE与能力GPA33结合和其用途和CD3

    公开(公告)号：EP3035956A2

    公开(公告)日：2016-06-29

    申请号：EP14837376.4

    申请日：2014-08-20

    申请人： MacroGenics, Inc.

    发明人： MOORE, Paul A. ,  LI, Jonathan ,  CHEN, Francine Zhifen ,  JOHNSON, Leslie S. ,  SHAH, Kalpana ,  BONVINI, Ezio

    IPC分类号： A61K39/00 ,  C12P21/08 ,  C07K16/00

    摘要： The present invention is directed to bi-specific monovalent diabodies that comprise two polypeptide chains and which possess at least one binding site specific for an epitope of CD3 and one binding site specific for an epitope of gpA33 (i.e., a "gpA33 x CD3 bi-specific monovalent diabody"). The present invention also is directed to bi-specific monovalent diabodies that comprise an immunoglobulin Fc domain ("bi-specific monovalent Fc diabodies") and are composed of three polypeptide chains and which possess at least one binding site specific for an epitope of gpA33 and one binding site specific for an epitope of CD3 ( i.e ., a "gpA33 x CD3 bi-specific monovalent Fc diabody"). The bi-specific monovalent diabodies and bi-specific monovalent Fc diabodies of the present invention are capable of simultaneous binding to gpA33 and CD3. The invention is directed to pharmaceutical compositions that contain such bi-specific monovalent diabodies or such bi-specific monovalent Fc diabodies. The invention is additionally directed to methods for the use of such diabodies in the treatment of cancer and other diseases and conditions.

    摘要翻译： 本发明涉及双特异性双抗体的单价确实包含两条多肽链和其中在gpA33（即，“gpA33 X CD3双抗体的表位具有特异性的CD3处的表位特异性针对至少一个结合位点和一个结合位点 具体单价双体“）。 因此，本发明涉及双特异性单价双抗体做了包括免疫球蛋白Fc结构域（“双特异性单价的Fc双抗体”）的和由三个多肽链和其具有特异于至少一个结合位点在gpA33的表位和 特异于CD3的表位的结合位点（即，一个“gpA33 X CD3双特异性单价的Fc双抗体”）。 所述双特异性单价双抗体和本发明的双特异性单价的Fc抗体是能够同时结合gpA33和CD3的。 本发明涉及药物组合物的确含有寻求双特异性单价双体或寻求双特异性单价的Fc双体。 本发明另外涉及用于在癌症和其它疾病和病症的治疗中使用的搜索双抗体的方法。

    COVALENT DIABODIES AND USES THEREOF
    15.
    发明公开
    COVALENT DIABODIES AND USES THEREOF 审中-公开

    公开(公告)号：EP3479844A1

    公开(公告)日：2019-05-08

    申请号：EP18191562.0

    申请日：2006-04-17

    申请人： MacroGenics, Inc.

    发明人： JOHNSON, Leslie S. ,  HUANG, Ling

    IPC分类号： A61K39/395 ,  C12P21/04 ,  C12P21/08 ,  C07K16/00 ,  C07H21/04 ,  C07K16/28 ,  C07K16/08 ,  C07K16/12 ,  C07K16/30 ,  C07K16/44

    摘要： The present invention is directed to diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers. The diabody molecules of the invention comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on the same or differing antigens. Additionally, the antigens may be from the same or different molecules. The individual polypeptide chains of the diabody molecule may be covalently bound through non-peptide bond covalent bonds, such as, but not limited to, disulfide bonding of cysteine residues located within each polypeptide chain. In particular embodiments, the diabody molecules of the present invention further comprise an Fc region, which allows antibody-like functionality to engineered into the molecule.

    COVALENT DIABODIES AND USES THEREOF
    16.
    发明公开
    COVALENT DIABODIES AND USES THEREOF 审中-公开

    公开(公告)号：EP3424951A1

    公开(公告)日：2019-01-09

    申请号：EP18187567.5

    申请日：2008-06-13

    申请人： MacroGenics, Inc.

    发明人： JOHNSON, Leslie S. ,  HUANG, Ling

    IPC分类号： C07K16/00 ,  C12P21/08 ,  C07K16/28 ,  C07K16/46

    摘要： The present invention is directed to diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers. The diabody molecules of the invention comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on the same or differing antigens. Additionally, the antigens may be from the same or different molecules. The individual polypeptide chains of the diabody molecule may be covalently bound through non- peptide bond covalent bonds, such as, but not limited to, disulfide bonding of cysteine residues located within each polypeptide chain. In particular embodiments, the diabody molecules of the present invention further comprise an Fc region, which allows antibody- like functionality to engineered into the molecule.

    COVALENTLY BONDED DIABODIES HAVING IMMUNOREACTIVITY WITH PD-1 AND LAG-3, AND METHODS OF USE THEREOF
    18.
    发明公开
    COVALENTLY BONDED DIABODIES HAVING IMMUNOREACTIVITY WITH PD-1 AND LAG-3, AND METHODS OF USE THEREOF 审中-公开
    WITH免疫反应共价结合的双抗体具有PD-1和LAG-3及其方法使用

    公开(公告)号：EP3161004A1

    公开(公告)日：2017-05-03

    申请号：EP15811659.0

    申请日：2015-06-19

    申请人： MacroGenics, Inc.

    发明人： BONVINI, Ezio ,  JOHNSON, Leslie S. ,  SHAH, Kalpana ,  LA MOTTE-MOHS, Ross ,  MOORE, Paul A. ,  KOENIG, Scott

    IPC分类号： C07K16/28

    CPC分类号： C07K16/2803 ,  C07K16/2818 ,  C07K16/468 ,  C07K2317/31 ,  C07K2317/626 ,  C07K2317/74

    摘要： The present invention is directed to bi-specific diabodies that comprise two or more polypeptide chains and which possess at least one Epitope-Binding Site that is immunospecific for an epitope of PD-1 and at least one Epitope-Binding Site that is immunospecific for an epitope of LAG-3 (i.e., a “PD-I×LAG-3 bi-specific diabody”). More preferably, the present invention is directed to bi-specific diabodies that comprise four polypeptide chains and which possess two Epitope-Binding Sites that are immunospecific for one (or two) epitope(s) of PD-1 and two Epitope-Binding Site that are immunospecific for one (or two) epitope(s) of LAG-3 (i.e., a “PD-1×LAG-3 bi-specific, tetra-valent diabody”).

    摘要翻译： 本发明涉及双特异性双抗体做了包括两个或多个多肽链，并且具有至少一个表位结合位点所做的是在PD-1和至少一个表位结合位点的表位做免疫特异性是免疫特异性在 LAG-3的表位（即， “PD-1×LAG-3双特异性双抗体”）。 更优选地，本发明涉及双特异性双抗体确实包含四个多肽链和其具有两个表位结合位点没有免疫特异性针对PD-1的一个（或两个）的表位（S）和两个表位结合位点没 是免疫特异性为LAG-3中的一个（或两个）的表位（多个）（即， “PD-1×LAG-3双特异性，四价双抗体”）。

    BI-SPECIFIC MONOVALENT FC DIABODIES THAT ARE CAPABLE OF BINDING CD32B AND CD79B AND USES THEREOF
    20.
    发明公开
    BI-SPECIFIC MONOVALENT FC DIABODIES THAT ARE CAPABLE OF BINDING CD32B AND CD79B AND USES THEREOF 审中-公开
    BISPEZIFISCHE MONOVALENTE FC-DIAKÖRPERZUR BINDUNG VON CD32B UND CD79B SOWIE VERWENDUNGEN DAVON

    公开(公告)号：EP3030264A1

    公开(公告)日：2016-06-15

    申请号：EP14834798.2

    申请日：2014-08-06

    申请人： MacroGenics, Inc.

    发明人： JOHNSON, Leslie S. ,  HUANG, Ling ,  SHAH, Kalpana ,  BONVINI, Ezio ,  MOORE, Paul A. ,  CHEN, Wei

    IPC分类号： A61K39/395

    CPC分类号： C07K16/283 ,  A61K2039/505 ,  C07K16/2803 ,  C07K16/468 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/60 ,  C07K2317/624 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2319/31 ,  C07K2319/73

    摘要： The present invention is directed to bi-specific monovalent diabodies that comprise an immunoglobulin Fc Domain ("bi-specific monovalent Fc diabodies") and are composed of three polypeptide chains and which possess at least one binding site specific for an epitope of CD32B and one binding site specific for an epitope of CD79b (i.e., a "CD32B x CD79b bi-specific monovalent Fc diabody"). The bi-specific monovalent Fc diabodies of the present invention are capable of simultaneous binding to CD32B and CD79b. The invention is directed to such compositions, to pharmaceutical compositions that contain such bi-specific monovalent Fc diabodies and to methods for their use in the treatment of inflammatory diseases or conditions, and in particular, systemic lupus erythematosus (SLE) and graft vs. host disease.

    摘要翻译： 本发明涉及包含免疫球蛋白Fc结构域（“双特异性单价Fc双抗体”）的双特异性单抗双抗体，并且由三条多肽链组成，并且其具有至少一个对CD32B的表位有特异性的结合位点和一个 CD79b表位特异性结合位点（即“CD32B×CD79b双特异性单价Fc双抗体”）。 本发明的双特异性单价Fc双抗体能够同时结合CD32B和CD79b。 本发明涉及这样的组合物，含有这种双特异性单价Fc双抗体的药物组合物及其用于治疗炎性疾病或病症，特别是系统性红斑狼疮（SLE）和移植物抗宿主 疾病。